Last reviewed · How we verify
dtEC→dtT
dtEC→dtT is a sequential chemotherapy regimen combining docetaxel and epirubicin followed by docetaxel and paclitaxel for breast cancer treatment.
dtEC→dtT is a sequential chemotherapy regimen combining docetaxel and epirubicin followed by docetaxel and paclitaxel for breast cancer treatment. Used for Breast cancer (neoadjuvant or adjuvant treatment).
At a glance
| Generic name | dtEC→dtT |
|---|---|
| Also known as | Epirubicin, Cyclophosphamide, Taxotere |
| Sponsor | Karolinska University Hospital |
| Drug class | Chemotherapy regimen (combination) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This is a neoadjuvant or adjuvant chemotherapy schedule designed to deliver multiple cytotoxic agents in a sequential manner to maximize tumor cell kill while managing tolerability. The regimen alternates between different drug combinations to potentially reduce resistance and optimize therapeutic benefit in breast cancer patients.
Approved indications
- Breast cancer (neoadjuvant or adjuvant treatment)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Alopecia
- Peripheral neuropathy
- Cardiotoxicity
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- dtEC→dtT CI brief — competitive landscape report
- dtEC→dtT updates RSS · CI watch RSS
- Karolinska University Hospital portfolio CI